Bind Therapeutics' BIND-014 enters midstage trial for prostate cancer

08/19/2013 | American City Business Journals

Bind Therapeutics said it has started dosing the first patient in a midstage trial of BIND-014 against metastatic castrate-resistant prostate cancer patients who have not previously received chemotherapy. BIND-014, a targeted molecule designed to deliver the cancer drug docetaxel, is also undergoing a midstage trial against nonsmall-cell lung cancer. Bind expects results of the two Phase II studies next year.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC